Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $333.62M | $124.46M | $52.16M | $10.10M | $7.57M | $5.28M | $2.61M | $42.00M |
| Cost of Revenue | $50.56M | $17.80M | $4.12M | $1.00M | $145.00K | $600.00K | $466.00K | $8.40M |
| Gross Profit | $283.06M | $106.66M | $48.04M | $9.10M | $7.43M | $4.68M | $2.14M | $33.60M |
| Gross Margin | 84.85% | 85.70% | 92.11% | 90.10% | 98.08% | 88.64% | 82.13% | 80.00% |
| Operating Expenses | $311.01M | $169.94M | $111.80M | $163.44M | $98.21M | $95.94M | $93.09M | $98.72M |
| Operating Income | $-27.95M | $-63.28M | $-63.76M | $-154.35M | $-90.78M | $-91.26M | $-90.95M | $-65.11M |
| Operating Margin | -8.38% | -50.84% | -122.24% | -1528.63% | -1199.05% | -1728.14% | -3488.57% | -155.04% |
| Net Income | $-39.14M | $-66.07M | $-67.21M | $-158.16M | $-94.31M | $-94.94M | $-91.30M | $-64.34M |
| Net Margin | -11.73% | -53.08% | -128.85% | -1566.46% | -1245.71% | -1797.77% | -3502.03% | -153.19% |
| EPS (Basic) | $-0.17 | $-0.30 | $-0.42 | $-1.52 | $-1.05 | $-1.47 | $-1.62 | $-1.36 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |